RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Arbutus Biopharma Stock

Arbutus Biopharma EBIT 2024

Arbutus Biopharma EBIT

-79.88 M USD

Ticker

ABUS

ISIN

CA03879J1003

WKN

A14XMD

In 2024, Arbutus Biopharma's EBIT was -79.88 M USD, a 2.27% increase from the -78.1 M USD EBIT recorded in the previous year.

The Arbutus Biopharma EBIT history

YEAREBIT (undefined USD)
2029e-
2028e-53.62
2027e-46.41
2026e-93.44
2025e-82.27
2024e-79.88
2023-78.1
2022-65.46
2021-73.52
2020-57.75
2019-71.17
2018-70.17
2017-70.13
2016-100.29
2015-55.26
2014-32.97
2013-12.15
2012-12.94
2011-10.69
2010-6.41
2009-7.43
2008-8.96
20072.44
20064.64
2005-1.05
2004-21.62

Arbutus Biopharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Arbutus Biopharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Arbutus Biopharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Arbutus Biopharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Arbutus Biopharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Arbutus Biopharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Arbutus Biopharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Arbutus Biopharma’s growth potential.

Arbutus Biopharma Revenue, EBIT and net profit per share

DateArbutus Biopharma RevenueArbutus Biopharma EBITArbutus Biopharma Net Income
2029e177.81 M undefined0 undefined57.84 M undefined
2028e57.78 M undefined-53.62 M undefined-40.53 M undefined
2027e9.66 M undefined-46.41 M undefined-36.6 M undefined
2026e8.7 M undefined-93.44 M undefined-82.8 M undefined
2025e6.34 M undefined-82.27 M undefined-67.24 M undefined
2024e7.23 M undefined-79.88 M undefined-74.21 M undefined
202318.14 M undefined-78.1 M undefined-72.85 M undefined
202239.02 M undefined-65.46 M undefined-69.46 M undefined
202110.99 M undefined-73.52 M undefined-88.39 M undefined
20206.91 M undefined-57.75 M undefined-75.87 M undefined
20196.01 M undefined-71.17 M undefined-164.87 M undefined
20185.95 M undefined-70.17 M undefined-67.15 M undefined
201710.7 M undefined-70.13 M undefined-85.32 M undefined
20161.49 M undefined-100.29 M undefined-384.16 M undefined
201523.28 M undefined-55.26 M undefined-62.72 M undefined
201414.95 M undefined-32.97 M undefined-38.84 M undefined
201315.46 M undefined-12.15 M undefined-14.06 M undefined
201214.11 M undefined-12.94 M undefined29.61 M undefined
201116.81 M undefined-10.69 M undefined-10.08 M undefined
201020.73 M undefined-6.41 M undefined-12.05 M undefined
200912.65 M undefined-7.43 M undefined-7.67 M undefined
200810.99 M undefined-8.96 M undefined-28.04 M undefined
200714.69 M undefined2.44 M undefined-2.43 M undefined
200613.98 M undefined4.64 M undefined18.58 M undefined
200512.75 M undefined-1.05 M undefined-7.73 M undefined
200411.25 M undefined-21.62 M undefined-25.93 M undefined

Arbutus Biopharma stock margins

The Arbutus Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Arbutus Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Arbutus Biopharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Arbutus Biopharma's sales revenue. A higher gross margin percentage indicates that the Arbutus Biopharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Arbutus Biopharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Arbutus Biopharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Arbutus Biopharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Arbutus Biopharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Arbutus Biopharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Arbutus Biopharma Margin History

Arbutus Biopharma Gross marginArbutus Biopharma Profit marginArbutus Biopharma EBIT marginArbutus Biopharma Profit margin
2029e0 %0 %32.53 %
2028e0 %-92.79 %-70.15 %
2027e0 %-480.67 %-379.13 %
2026e0 %-1,074.1 %-951.82 %
2025e0 %-1,297.56 %-1,060.57 %
2024e0 %-1,104.53 %-1,026.15 %
20230 %-430.53 %-401.57 %
20220 %-167.76 %-178.01 %
20210 %-668.97 %-804.28 %
20200 %-835.75 %-1,097.97 %
20190 %-1,184.19 %-2,743.26 %
20180 %-1,179.33 %-1,128.57 %
20170 %-655.42 %-797.38 %
20160 %-6,730.87 %-25,782.55 %
20150 %-237.37 %-269.42 %
20140 %-220.54 %-259.8 %
20130 %-78.59 %-90.94 %
20120 %-91.71 %209.85 %
20110 %-63.59 %-59.96 %
20100 %-30.92 %-58.13 %
20090 %-58.74 %-60.63 %
20080 %-81.53 %-255.14 %
20070 %16.61 %-16.54 %
20060 %33.19 %132.9 %
20050 %-8.24 %-60.63 %
20040 %-192.18 %-230.49 %

Arbutus Biopharma Aktienanalyse

What does Arbutus Biopharma do?

Arbutus Biopharma Corp is a biopharmaceutical company that focuses on developing novel treatment methods for viral diseases. The company, based in Vancouver, Canada, was founded in 2008. The history of Arbutus Biopharma Corp began with the merger of Tekmira Pharmaceuticals and OnCore Biopharma in 2015. The merger strengthened the company and expanded its ability to develop innovative therapies for Hepatitis B and Hepatitis D viruses. The ability to bring the companies together also demonstrates the team, consisting of experienced experts from various areas such as the healthcare industry, biotech engineering, finance, and pharmacy. The business model of Arbutus Biopharma Corp is to explore, develop, and market novel treatment methods for viral diseases. Marketing is done through partnerships with other companies that commercialize the products. The company relies on research and development agreements to enter into synergistic partnerships that work on the same wavelength. One of the key divisions of Arbutus Biopharma Corp is the development of RNA interference (RNAi) therapies. These therapies aim to suppress the genetic information that leads to viral replication in cells. The company has an extensive patent portfolio and comprehensive expertise in the field of RNAi therapy. RNAi therapy opens up a new paradigm in the treatment of viral diseases. The company has also developed products such as the HBV Antisense platform. The HBV Antisense platform utilizes a special type of RNA-based medication to suppress the production of proteins necessary for the replication of the Hepatitis B virus. This strategy allows for the reduction of viral RNA replication and strengthens the immune system to fight against or prevent viral infections. The company also pursues an advanced pipeline in the preclinical phase to develop a melanocortin receptor antagonist and an artificial antibody against Hepatitis B. Another business area of Arbutus Biopharma Corp is collaboration with other companies to outsource innovative technologies and products. One of the key partnerships is with Roivant Sciences Ltd. Roivant Sciences Ltd is a pharmaceutical company that focuses on the development and commercialization of innovative therapy approaches. The partnership between Arbutus Biopharma Corp and Roivant Sciences Ltd creates a win-win situation for both, bringing about synergies and enabling capital and risk sharing. In summary, Arbutus Biopharma Corp is a biopharmaceutical company that focuses on the development of novel therapies for viral diseases. The company has a broad portfolio of innovative products in the field of RNAi therapy and HBV Antisense platform. Arbutus Biopharma Corp strives to achieve advancements in the development of therapies for viral diseases through partnerships and alliances with other companies. Arbutus Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Arbutus Biopharma's EBIT

Arbutus Biopharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Arbutus Biopharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Arbutus Biopharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Arbutus Biopharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Arbutus Biopharma stock

How much did Arbutus Biopharma achieve in EBIT for the current year?

In the current year, Arbutus Biopharma has achieved an EBIT of -79.88 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Arbutus Biopharma.

How has the EBIT of Arbutus Biopharma developed in recent years?

The EBIT of Arbutus Biopharma has increased by 2.274% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Arbutus Biopharma?

The EBIT of Arbutus Biopharma is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Arbutus Biopharma pay?

Over the past 12 months, Arbutus Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arbutus Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Arbutus Biopharma?

The current dividend yield of Arbutus Biopharma is .

When does Arbutus Biopharma pay dividends?

Arbutus Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Arbutus Biopharma?

Arbutus Biopharma paid dividends every year for the past 0 years.

What is the dividend of Arbutus Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Arbutus Biopharma located?

Arbutus Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Arbutus Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Arbutus Biopharma from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Arbutus Biopharma pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Arbutus Biopharma in the year 2023?

In the year 2023, Arbutus Biopharma distributed 0 USD as dividends.

In which currency does Arbutus Biopharma pay out the dividend?

The dividends of Arbutus Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Arbutus Biopharma stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Arbutus Biopharma

Our stock analysis for Arbutus Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arbutus Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.